Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSPS + Colyte refers to a combination bowel cleansing regimen consisting of Oral Sodium Phosphate Solution (OSPS) and Colyte, a polyethylene glycol-electrolyte lavage solution (PEG-ELS). This regimen is primarily indicated for colonic cleansing prior to colonoscopy or other diagnostic procedures. It combines the saline laxative properties of sodium phosphate, which induces fluid secretion into the small intestine, with the osmotic activity of PEG 3350, which promotes bowel evacuation. The combination is designed to improve patient tolerability by reducing the total volume of PEG solution required compared to standard high-volume preparations. A fixed-dose combination product containing these ingredients was previously marketed under the brand name Suclear, which was approved by the FDA in 2013 but subsequently discontinued. The use of sodium phosphate-containing preparations is associated with a risk of acute phosphate nephropathy, particularly in patients with renal impairment or those taking certain medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate + polyethylene glycol 3350 + sodium sulfate + sodium bicarbonate + sodium chloride + potassium chloride.